Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Treatments for primary and metastatic melanomas are rarely effective. Even therapeutics such as retinoic acid (RA) that are successfully used to treat several other forms of cancer are ineffective. Recent evidence indicates that the antiproliferative effects of RA are mediated by the transcription factor SOX9 in human cancer cell lines. As we have previously shown that SOX9 is expressed in normal melanocytes, here we investigated SOX9 expression and function in human melanomas. Although SOX9 was expressed in normal human skin, it was increasingly downregulated as melanocytes progressed to the premalignant and then the malignant and metastatic states. Overexpression of SOX9 in both human and mouse melanoma cell lines induced cell cycle arrest by increasing p21 transcription and restored sensitivity to RA by downregulating expression of PRAME, a melanoma antigen. Furthermore, SOX9 overexpression in melanoma cell lines inhibited tumorigenicity both in mice and in a human ex vivo model of melanoma. Treatment of melanoma cell lines with PGD2 increased SOX9 expression and restored sensitivity to RA. Thus, combined treatment with PGD2 and RA substantially decreased tumor growth in human ex vivo and mouse in vivo models of melanoma. The results of our experiments targeting SOX9 provide insight into the pathophysiology of melanoma. Further, the effects of SOX9 on melanoma cell proliferation and RA sensitivity suggest the encouraging possibility of a noncytotoxic approach to the treatment of melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling
Epping, M. T., Wang, L., Edel, M. J., Carlée, L., Hernandez, M., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.07.003 · Cited by 432 · cited 3×
“PRAME acts as a dominant repressor of the RA receptor, and recent evidence indicates that silencing of PRAME restores sensitivity to RA (1, 2).”
BackgroundEssential role of Sox9 in the pathway that controls formation of cardiac valves and septa
Akiyama, H., Chaboissier, M.-C., Behringer, R. R., Rowitch, D. H., Schedl, A., Epstein, J. A., & de Crombrugghe, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401711101 · Cited by 265
Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Wellbrock, C., & Marais, R. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505059 · Cited by 196 · cited 2×
“This effect is achieved by 2 distinct mechanisms: (a) an indirect effect, whereby SOX9 activates MITF, which in turn acts on p21 and blocks melanoma proliferation (9, 11); and (b) a direct effect, whereby SOX9 directly binds the p21 promoter and increases its expression.”
Background
Cited by
Retinoids, Retinoic Acid Receptors, and Cancer
Tang, X.-H., & Gudas, L. J. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130303 · Cited by 596
The role of SOX family members in solid tumours and metastasis
Grimm, D., Bauer, J., Wise, P., Krüger, M., Simonsen, U., Wehland, M., Infanger, M., & Corydon, T. J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.004 · Cited by 487
Retinoids regulate stem cell differentiation
Gudas, L. J., & Wagner, J. A. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22417 · Cited by 395
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
The versatile functions of Sox9 in development, stem cells, and human diseases
Jo, A., Denduluri, S., Zhang, B., Wang, Z., Yin, L., Yan, Z., Kang, R., Shi, L. L., Mok, J., Lee, M. J., et al. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.09.004 · Cited by 366
Developmental Fate and Cellular Maturity Encoded in Human Regulatory DNA Landscapes
Stergachis, A. B., Neph, S., Reynolds, A., Humbert, R., Miller, B., Paige, S. L., Vernot, B., Cheng, J. B., Thurman, R. E., Sandstrom, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.020 · Cited by 338
Shakhova, O., Cheng, P., Mishra, P. J., Zingg, D., Schaefer, S. M., Debbache, J., Häusel, J., Matter, C., Guo, T., Davis, S., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1004877 · Cited by 111
“revealed that overexpression of SOX9 prevents melanoma formation [35] by increasing the expression of the CDK inhibitor p21 and subsequent cell cycle arrest.”
BackgroundCheng, P. F., Shakhova, O., Widmer, D. S., Eichhoff, O. M., Zingg, D., Frommel, S. C., Belloni, B., Raaijmakers, M. I., Goldinger, S. M., Santoro, R., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0594-4 · Cited by 100
“Overexpression of SOX9 was previously shown to drive melanoma cells into cell cycle arrest [29].”
BackgroundResultInfluentialSox13 promotes hepatocellular carcinoma metastasis by transcriptionally activating Twist1
Feng, M., Fang, F., Fang, T., Jiao, H., You, S., Wang, X., & Zhao, W. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-0445-0 · Cited by 25
Metadata
- Authors
- Passeron, T., Valencia, J. C., Namiki, T., Vieira, W. D., Passeron, H., Miyamura, Y., & Hearing, V. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-03-09
- Volume
- 119
- Issue
- 4
- Pages
- 954-63
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1993285835
- Cited by
- 116
- References
- 3
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.